NEOADJUVANT EFLORNITHINE AND BICALUTAMIDE COMPARED WITH EFLORNITHINE ALONE, BICALUTAMIDE ALONE, AND NO NEOADJUVANT THERAPY IN TREATING PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING BRACHYTHERAPY OR RADICAL PROSTATECTOMY: